Business Wire

Egle Therapeutics Receives €9.3 Million in State Funding Under the “Innovations in Biotherapies and Bioproduction” Call for Projects from France 2030

Share

Egle Therapeutics receives significant non-dilutive funding to accelerate the clinical development of its lead immuno-oncology therapeutic candidate, EGL-001, as part of the “Innovations in Biotherapies and Bioproduction” call for projects under the French government’s France 2030 initiative.

Egle Therapeutics, a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, today announced that it has secured €9.3 million in state funding under the “Innovations in Biotherapies and Bioproduction” call for projects from the France 2030 plan, managed on behalf of the French government by Bpifrance.

Founded in 2020 as a spin-off from Institut Curie, Egle Therapeutics is a clinical-stage biotechnology company specializing in immunomodulation, with the ambition to develop novel approaches to the modulation of Treg activity for the treatment of cancer and autoimmune diseases.

Egle Therapeutics has developed a proprietary translational platform to identify novel tumor-infiltrating Treg targets, with the aim of developing antibody-based candidate drugs to disable Treg function and restore an effective antitumor immune response.

In June 2020, Egle Therapeutics entered a strategic partnership with Takeda Pharmaceuticals, establishing a three-year research collaboration with an option agreement. Since its inception, the company has successfully raised nearly €56 million through equity financing and non-dilutive public funding, including the i-Lab Innovation Competition and DeepTech Development Grant.

During its Series A financing round in October 2021, the company raised €47 million, attracting renowned investors, including EQT Life Sciences, Bpifrance (INNOBIO 2 and Innovation 1), Fund Plus, Bioqube Factory Fund, T1D Fund, and Takeda Ventures.

In 2024, Egle Therapeutics achieved key milestones, including the launch of its Phase I/II clinical trial for EGL-001, the appointment of Michel Detheux as Chairman, and the appointment of Christophe Quéva as Chief Executive Officer.

“We are honored to receive this funding from the French government through France 2030. This recognition and immense support will help Egle Therapeutics advance its research and development programs in regulatory T cell modulation. The funding granted under the ‘Innovations in Biotherapies and Bioproduction’ call for projects will enable us to accelerate the development of EGL-001, our lead immuno-oncology therapeutic candidate. EGL-001 is currently being evaluated in a Phase I/II clinical trial in France and Spain.”

Christophe Quéva, CEO of Egle Therapeutics

About Egle Therapeutics

Egle Therapeutics is a biotechnology company specializing in the development of immunotherapies targeting regulatory T cells. Through its proprietary discovery platform, Egle identifies novel Treg-specific targets and develops innovative Treg-targeting therapeutic candidates for the treatment of cancer and autoimmune diseases.

Egle Therapeutics’ lead immuno-oncology candidate, EGL-001, is currently being evaluated in a Phase I/II clinical trial. In autoimmunity, the company has completed the regulatory studies and manufacturing for a CTA filing for EGL-003 and is preparing to launch a clinical trial in 2025.

For more information www.egle-tx.com

About France 2030

✔ A dual ambition: France 2030 aims to transform key economic sectors (such as healthcare, energy, automotive, aerospace, and space industries) through technological innovation while positioning France not just as a participant but as a global leader in tomorrow’s world. From fundamental research to idea generation, product development, and industrialization, France 2030 supports the entire innovation lifecycle.

✔ Unprecedented scale: France 2030 will invest €54 billion to help French companies, universities, and research institutions navigate ecological and economic transitions, ensuring they remain competitive and emerge as leaders in strategic industries. France 2030 commits to allocating 50% of its funding to decarbonization and 50% to emerging innovators, while adhering to sustainable investment principles (Do No Significant Harm).

✔ Collaborative implementation: Designed and deployed in consultation with economic, academic, local, and European stakeholders, France 2030 determines its strategic priorities through an open, competitive, and selective project application process. Selected projects receive state support to drive innovation and industrial growth.

✔ Led by the General Secretariat for Investment, on behalf of the Prime Minister, France 2030 is implemented by ADEME (Agency for Ecological Transition), ANR (National Research Agency), Bpifrance, and Banque des Territoires.

For more information: france2030.gouv.fr | @SGPI_avenir

About the Call for Projects “Innovations in Biotherapies and Bioproduction”

The call for projects “Innovations in Biotherapies and Bioproduction” is a funding initiative within the France 2030 strategy, specifically under the “Biotherapies and Bioproduction of Innovative Therapies” acceleration plan. Led by the Health Innovation Agency within the Secretariat General for Investment, the program supports excellence in biotherapy research by accelerating technology transfer and ensuring a continuous pipeline of innovations from bench to bedside.

About Bpifrance

Bpifrance provides funding solutions to businesses at every stage of their development, including loans, guarantees, and equity investment. Bpifrance also supports innovation and international expansion through offers a wide range of export financing solutions.

Additionally, Bpifrance provides advisory services, networking opportunities, and business acceleration programs for startups, small- and mid-sized enterprises. With 50 regional offices, Bpifrance ensures entrepreneurs receive close and effective support to tackle their challenges.

For more information: www.bpifrance.fr

View source version on businesswire.com: https://www.businesswire.com/news/home/20250317147647/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Logitech Announces Q4 and Full Fiscal Year 2025 Results29.4.2025 22:03:00 CEST | Press release

A Year of Broad-Based Sales Growth, Expanded Market Share and Increased Profitability, Driven by Strategic Priorities SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the fourth quarter and full Fiscal Year 2025 ended March 31, 2025. For Fiscal Year 2025: Sales were $4.55 billion, up 6 percent in US dollars and 7 percent in constant currency, compared to the prior year. GAAP operating income was $655 million, up 11 percent compared to the prior year. Non-GAAP operating income was $775 million, up 11 percent compared to the prior year. GAAP earnings per share (EPS) was $4.13, up 7 percent compared to the prior year. Non-GAAP EPS was $4.84, up 14 percent compared to the prior year. Cash flow from operations was $843 million. The year-ending cash balance was $1.5 billion. The Company returned $797 million of cash to shareholders through its annual dividend payment and share repurchases.

U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene29.4.2025 21:32:00 CEST | Press release

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the U.S. Patent and Trademark Office (USPTO) rendered a Final Written Decision invalidating all claims of Pharmacyclics LLC’s (Pharmacyclics) U.S. Patent No. 11,672,803 (the ‘803 patent) that were challenged by BeiGene in a post-grant review (PGR) proceeding. On November 1, 2023, BeiGene filed a PGR petition with the USPTO challenging the validity of certain claims of the ‘803 patent, in response to a patent infringement lawsuit Pharmacyclics brought against BeiGene concerning BRUKINSA® (zanubrutinib). On May 1, 2024, the USPTO granted BeiGene’s petition to institute the PGR. The USPTO’s Final Written Decision is appealable by Pharmacyclics. Commenting on the ruling, BeiGene General Counsel Chan Lee said: “We are pleased that the USPTO invalidated all challenged claims of the ‘803 patent. Today’s decision reinforces our belief th

One out of Three Secure Civil IDs Delivered Each Year Is Powered by Thales29.4.2025 16:50:00 CEST | Press release

In a world where identity fraud represents a critical vulnerability for citizens and societies, Thales is leading the transformation of civil identity into a secure and citizen-first service. Through its advanced Civil Identity Suite, Thales enables governments worldwide to protect their citizens, ensuring protection at every stage of the identity journey and for the entire identity chain. Supporting more than 300 national identity programmes and having enrolled over 500 million people, Thales is uniquely positioned to deliver secure and responsible identity solutions. Each year, Thales powers one in three smart civil IDs (official electronic documents) issued worldwide, highlighting the company’s key role in shaping the future of identities and helping governments and citizens transition smoothly to digital. With its Civil Identity Suite, Thalesenables the issuance and management of both physical and digital identities, as well as all means of enrolling citizens and enabling seamless

Solving Border Control Staffing Challenges: Regula Launches an Ecosystem for Remote Document Examination29.4.2025 15:00:00 CEST | Press release

Regula, a global developer of forensic devices and identity verification solutions, introduces an innovative solution designed to transform document examination processes, particularly in border control operations. Based on high-resolution photospectral scanners from the Regula 88XX product line, it enables highly accurate and reliable remote document authentication, effectively addressing the pressing issue of staffing shortages in border security. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250429852027/en/ High-resolution photospectral scanner Regula 8880 for remote document verification (Photo: Regula) Traditionally, document authenticity experts needed to be physically present at each checkpoint. However, this requirement has become increasingly challenging due to current staffing constraints. For example, a recent European Commission report highlights gaps in the availability of certain specialized experts, notably

Boomi CEO Steve Lucas’ New Book ‘Digital Impact’ Becomes a National Bestseller, Topping USA Today andPublishersWeekly Lists29.4.2025 15:00:00 CEST | Press release

“Digital Impact: The Human Element of AI-Driven Transformation” earns top rankings as business leaders embrace its timely message on the responsible use of AI Boomi™, the intelligent integration and automation leader, today announced that Chairman and CEO Steve Lucas is now a national bestselling author with the release of his new book, Digital Impact: The Human Element of AI-Driven Transformation (Wiley). Since its debut, the book has rapidly climbed national bestseller charts — including multiple appearances on USA TODAY’s Bestselling Books lists, and Publishers Weekly Bestseller List. Digital Impact resonates deeply with business leaders navigating the intersection of AI and human-centered innovation, offering a timely blueprint for more thoughtful, effective digital transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250429280721/en/ Boomi CEO Steve Lucas’ New Book ‘Digital Impact’ Becomes a National Bestselle

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye